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Abstract Here we present the synthesis, pharmacological
activity, and molecular docking of novel non-competitive
antagonists of GluK2 receptor. The compounds concerned
are derivatives of indole and carbazole and are the second
reported series of non-competitive antagonists of the
GluK2 receptor (the first one was also published by our
group). The activity of the indole derivatives is in the
micromolar range, as in the case of the first series of non-
competitive GluK2 receptor antagonists. We have found
that designed carbazole derivatives are devoid of activity.
Active indole derivatives interact with the transduction
domain of the GluK2 receptor, i.e., the domain which links
the transmembrane region of the receptor with the agonist-
binding domain. The binding pocket is situated within one
receptor subunit.
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Introduction
The glutamatergic system is an attractive molecular target
for pharmacological intervention (Kaczor and Matosiuk,
2010). Ligands acting on ionotropic glutamate receptors
(iGluRs: NMDA, AMPA, and kainate receptors) or
metabotropic glutamate receptors (mGluRs) are potential
drug candidates for the treatment of neurodegenerative
diseases (Alzheimer’s disease, Parkinson’s disease, Hun-
tington’s disease), epilepsy, as well as schizophrenia,
anxiety, and memory disorders (Kew and Kemp, 2005).
Although only a few glutamate receptor ligands have
turned out to be clinically useful (firstly, because of the
crucial role of the glutamatergic system in many physio-
logical processes, and secondly, due to the unfavorable
psychotropic side effects, traditionally linked with high-
affinity NMDA receptor antagonists), ligands of kainate
receptors seem to be especially promising. Kainate recep-
tors are involved in epileptogenesis and inducing synaptic
plasticity, mainly via the mossy fiber long-term potentia-
tion mechanism. Thus, antagonists of kainate receptors are
potential anti-seizure and neuroprotective agents. More-
over, non-competitive antagonists of AMPA receptors are
well tolerated in preclinical and clinical studies (Sze´na´si
et al., 2008), thus it may be expected that this will also be
the case for such ligands of kainate receptors.
Research on non-competitive antagonists of kainate
receptors is hindered by the fact that only three series of
such compounds have been obtained up to now (Kaczor
et al., 2012; Valgeirsson et al., 2003, 2004). Recently, we
have reported 1,2,3,5-tetrasubstituted indole derivatives
which are among the most active non-competitive antag-
onists of the GluK1 receptor and are the first known such
ligands of the GluK2 receptor, Fig. 1 (Kaczor et al., 2012).
We have also suggested a binding site for them in the
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receptor transduction domain (Kaczor et al., 2014) which
was enabled by the construction of whole receptor models
(Kaczor et al., 2008, 2009, 2014). Here we present further
modifications, 2–7, of the lead compound E099-25011, (1-
ethyl-5-methoxy-2-(4-methoxyphenyl)-3-methylindole), 1.
The lead compound was identified by searching the internal
databases of compounds at the Elbion Institute, Radebul,
Germany. 1 is an analog of Zindoxifene, an anti-estrogen,
tumor-inhibiting compound (Schneider et al., 1991). We
have previously optimized compound 1 by changing sub-
stituents in positions 1, 2, 3, and 5 of the indole system
(Fig. 1) (Kaczor et al., 2012, 2014). Compounds 3 and 5–7
were tested for their affinity to the GluK2 receptor, and
compounds 3 and 5 were found to be non-competitive
antagonists at this receptor. Furthermore, we show how
novel non-competitive antagonists 3 and 5 of the GluK2
receptor interact with the transduction domain of the pre-
viously constructed homology model of this receptor
(Kaczor et al., 2014).
Materials and methods
Chemistry
Reactions were routinely monitored by thin-layer chro-
matography (TLC) in silica gel (60 F254 Merck plates) and
the products were visualized with ultraviolet light at
254 nm. All NMR spectra were acquired on a Bruker
AVANCE III 600 MHz spectrometer equipped with a BBO
Z-gradient probe. Spectra were recorded at 25 C using
chloroform as a solvent with a non-spinning sample in
5 mm NMR-tubes. High resolution mass spectra (HRMS)
were recorded on a Bruker microTOF-Q II and processed
using Compass Data Analysis software. The elementary
analysis was performed using a Perkin-Elmer analyzer.
Melting points were determined with Boetius apparatus
and are uncorrected.
5-methoxy-3-methyl-2-(2-thienyl)indole (2)
Colorless crystalline needles (EtOH). This compound was
prepared from 0.05 mol of 4-methoxyphenylhydrazine
hydrochloride, 0.05 mol of 1-(2-thienyl)propan-1-one (2-
propionylthiophene), 100 ml of anhydrous ethanol, and
10 ml of ethanol saturated with HCl, which were mildly
boiled in a round-bottomed flask with a reflux condenser
for 4 h. The reaction mixture was left overnight. The pre-
cipitation obtained was filtered and purified by crystalli-
zation from ethanol and repeated washing with n-hexane.
Because of the tendency of the products to photooxidation,
they had to be kept in the dark in a refrigerator. Yield:
69 %, mp 100–102 C. 1H NMR (600 MHz, CDCl3)
d = 10.82 (s, 1H, NH), 7.47 (dd, J = 1.2, 5.3 Hz, 1H,
H-para thienyl), 7.25 (d, J = 8.8, 1H, H-7), 7.19 (dd,
J = 3.6, 5.3 Hz, 1H, H-meta thienyl), 7.11 (dd, J = 1.2,
3.6 Hz, 1H, H-ortho thienyl), 7.04 (d, J = 2.4, 1H, H-4),
6.93 (dd, J = 2.4, 8.8 Hz, 1H, H-6), 3.78 (s, 3H, 5-OMe),
2.29 (s, 3H, 3-Me); 13C NMR (125 MHz, CDCl3)
d = 151.93(C-5), 132.85 (Cipso thienyl), 131.04 (C-7a),
127.33 (C-2), 124.76 (C-ortho thienyl), 124.05 (C-meta
thienyl), 122.95 (C-para thienyl), 122.41 (C-3a), 113.91
(C-6), 110.74 (C-3), 110.23 (C-7), 100.68 (C-4), 55.95 (C-
5-OMe), 9.65 (C-3-Me); HRMS (EI) m/z: 243.3278
C14H13NOS (calcd 243.3282); Anal. Calcd for
C14H13NOS: C, 69.10; H, 5.38; N, 5.76; S, 13.18. Found:
C, 69.16; H, 5.42; N, 5.74; S, 13.14.
1-(2-thienyl)propan-1-one (2-propionylothiophene)
0.25 mol (32.53 g) of propionic acid anhydride and 0.2 mol
(16.83 g) of thiophene were heated to 60 C in a three-
necked flask, equipped with a mechanic mixer, air con-
denser, and thermometer. Next, while still mixing, 1.10 g of
85 % orthophosphoric (V) acid was slowly added. Heating
was continued for 2.5 h at 125 C (with the mixture getting
darker). After cooling, the mixture was washed with 50 ml of
water and 100 ml of 10 % solution of sodium carbonate. The
organic layer was dried with anhydrous sodium sulfate and
subjected to vacuum distillation. The fraction boiling at
99–103/14 mmHg was collected. bp 88 C/7 mmHg (Har-
though and Kosak, 1947). Yield 12.90 g (46 %).
5-methoxy-1,3-dimethyl-2-(2-thienyl)indole (3)
Colorless crystalline needles (EtOH). This compound was
prepared from 0.4 g of sodium hydride (50 % oil suspen-
sion) and 10 ml of anhydrous DMF, which were placed in a
three-necked round-bottomed flask, equipped with a
mechanic mixer and a thermometer. The mixture was
cooled to 0 C, and then a solution of 0.001 mol of
Fig. 1 Non-competitive antagonists of GluK1/GluK2 receptors
(Kaczor et al., 2012)
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5-methoxy-3-methyl-2-(2-thienyl)indole (2) in 10 ml of
anhydrous DMF was added dropwise. The mixture was
stirred for 45 min, and a solution of 0.001 mol of methyl
sulfate in 5 ml of anhydrous DMF was added. After
20 min, the ice bath was removed and the mixing was
continued for 1.5 h at room temperature. Then a few mil-
liliters of water were carefully added to decompose the
excess of sodium hydride. The reaction mixture was fil-
tered, the filtrate was cooled, and 20 ml of water was added
to it. The precipitation obtained was purified by crystalli-
zation from ethanol and repeated washing with n-hexane.
Yield 41 %, mp 71–73 C. 1H NMR (600 MHz, CDCl3)
d = 7.43 (dd, J = 1.2, 5.3 Hz, 1H, H-para thienyl), 7.21
(d, J = 8.8 Hz, 1H, H-7), 7.15 (dd, J = 3.6, 5.3 Hz, 1H,
H-meta thienyl), 7.08 (dd, J = 1.2, 3.6 Hz, 1H, H-ortho
thienyl), 7.01 (d, J = 2.4 Hz, 1H, H-4), 6.89 (dd, J = 2.4;
8.8 Hz, 1H, H-6), 3.74 (s, 3H, 5-OMe), 2.25 (s, 3H, 3-Me),
1.24 (s, 3H, 1-Me); 13C NMR (125 MHz, CDCl3)
d = 152.09 (C-5), 132.83 (Cipso thienyl), 131.36 (C-7a),
128.71 (C-2), 122.53(C-ortho thienyl), 123.12 (C-meta
thienyl), 123.08 (C-para thienyl), 121.69 (C-3a), 113.18
(C-6), 110.77 (C-3), 110.25 (C-7), 100.73 (C-4), 56.03 (C-
5-OMe), 15.42 (N1-Me), 9.61 (C-3-Me); HRMS (EI): m/
z 257.3552 C15H15NOS (calcd 257.3553); Anal. Calcd for
C15H15NOS: C, 70.01; H, 5.87; N, 5.44; S, 12.46. Found:
C, 69.95; H, 5.92; N, 5.48; S, 12.41.
1-(1H-Indol-3-yl)-3-phenylprop-2-en-1-one (4)
Derivative 4 was obtained by means of Friedel–Crafts
acylation according to (Guchhait et al., 2011) in 7.5 %
yield as a yellowish white solid; mp 225-230 C. Spectral
data according to (Guchhait et al., 2011).
3-[1-(4-chlorobenzyl)-1H-indol-5-yl]-1-phenylprop-
2-en-1-one (5)
Yellowish solid (EtOH). This compound was prepared as
follows: 0.01 mol of derivative 4 and 30 ml of anhydrous
DMF were mixed in a round-bottomed flask equipped with
a thermometer and a dropping funnel. The reaction mixture
was cooled to 0 C and 0.8 g of sodium hydride was added
(50 % oil suspension). After 30 min of mixing, a solution
of 0.012 mol of 4-chlorobenzyl chloride in 20 ml of
anhydrous DMF was added dropwise. The reaction was
continued at room temperature for 3 h. The mixture was
filtered and 10–15 ml of water was added to the filtrate.
The resulting resin-like substance was removed and the
next portion of water (25–30 ml) was added until the
solution becomes opaque. The mixture was kept in
refrigeration for two hours and the precipitation obtained
was filtered and purified by crystallization from ethanol
and repeated washing with n-hexane. Yield 72.0 %, mp
235–238 C, 1H NMR (600 MHz, CDCl3) d = 8.64–8.54
(m, 1H, H-5), 7.92 (s, 1H, H-2), 7.85 (d, J = 15.5 Hz, 1H,
H-4), 7.65 (s, 2H, CH), 7.46–7.26 (m, 9H, Ar, phe-
nyl ? benzyl), 7.13–7.09 (m, 2H, H-6, H-7), 5.35 (s, 2H,
CH2);
13C NMR (151 MHz, CDCl3) d = 184.47 (CO),
141.40 (C-2) 140.71 (Cipso phenyl), 137.11 (CHCHCO),
135.34 (C-7a), 134.51 (Cipso benzyl), 134.37 (C-para ben-
zyl), 134.17 (C-ortho phenyl), 129.94 (C-para phenyl),
129.29 (C-meta benzyl), 128.88 (C-meta phenyl), 128.21
(CHCHCO), 127.09 (C-ortho benzyl), 123.97 (C-3a),
123.85 (C-6), 123.24 (C-5), 122.98 (C-4), 118.43 (C-3),
110.13 (C-7), 50.20 (CH2). HRMS (EI): m/z 371.8434
C24H18NOCl (calcd 371.8591); Anal. Calcd for
C24H18NOCl C, 77.51; H, 4.87; N, 3.77; Cl, 9.53. Found:
C, 77.55; H, 4.88; N, 3.73; S, 9.49.
9H-4-oxo-1,2,3,4-tetrahydrocarbazole (6)
A solution of 0.1 mol of phenylhydrazine in 150 ml of
water was added dropwise for 1.5 h to a solution of 1,3-
cyclohexadione in 100 ml of water. The orange precipita-
tion of 1,3-cyclohexadione monophenylhydrazone
obtained was filtered. Yield 99 %, mp 173.5 C (Hester,
1969). 100 g of polyphosphoric acid (PPA) was heated to
80 C and then 0.025 mol of monophenylhydrazone of 1,3-
cyclohexadione was added. The temperature slowly
increased to 110 C due to an exothermic reaction. The
reactants were mixed for 30 min and then the reaction
mixture was poured onto ice. The precipitation obtained
was filtered and crystallized from methanol. Derivative 6
was obtained in a 61.6 % yield as a colorless solid, mp
234–235 C. Spectral data as described by (Rodriguez
et al., 1989).
9-(4-chlorobenzyl)-4-oxo-1,2,3,4-tetrahydrocarbazole (7)
Colorless solid (EtOH). This compound was prepared as
follows: 25 ml of DMF, 0.1 ml of water, and 0.013 mol of
potassium hydroxide were mixed for 5 min. 0.01 mol of 6
was added and mixing was continued for 1 h. Then a
solution of 0.0015 mol of 4-chlorobenzyl chloride in 10 ml
of DMF was added dropwise and the reaction was con-
tinued under stirring for 2 h. The reaction mixture was kept
in a refrigerator overnight. 5 ml of water was added and the
first portion of precipitation was obtained and filtered. The
second portion of precipitation was obtained after adding a
further 15 ml of water. The combined precipitation was
crystallized from ethanol. Yield 87.7 %, mp 171–173 C.
1H NMR (500 MHz, CDCl3) 7.58 (d, 1H, J = 7.8, H-5),
7.33 (d, 1H, J = 8.0, H-8), 7.22 (dd, 1H, J = 7.2; 8.0,
H-7), 7.20 (d, 2H, J = 8.4, H-meta benzyl), 7.13 (dd, 1H,
J = 7.2;7.8, H-6), 6.87 (d, 2H, J = 8.4, H-ortho benzyl),
5.17 (s, 2H, CH2), 2.90 (m, 2H, H-1), 2.59 (m, 2H, H-3),
812 Med Chem Res (2015) 24:810–817
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2.25 (m, 2H, H-2), 13C NMR (100 MHz, CDCl3) 163.32
(CO), 158.25 (C-9a), 148.73 (Cipso benzyl), 139.25 (C-8a),
127.81 (C-para benzyl), 123.97 (C-meta benzyl), 123.85
(C-ortho benzyl), 116.08 (C-4b), 115.64 (C-7), 113.97 (C-
6), 112.82 (C5), 111.09 (C-4a), 105.46 (C-8), 20.95 (CH2),
13.51 (C-3), 13.05 (C-1), 12.73 (C-2). HRMS (EI) m/z:
309.7822 C19H16NOCl (calcd 309.7890); Anal. Calcd for
C19H16NOCl C, 73.66; H, 5.21; N, 4.52; Cl, 11.44. Found:
C, 73.65; H, 5.22; N, 4.53; S, 11.41.
Pharmacology
The pharmacological studies were performed as described
previously (Kaczor et al., 2012). HEK293 lines expressing
GluK2 kainate receptors, together with aequorin, a biolu-
minescent Ca2? reporter protein, were used to determine
the effect of the compounds being investigated on GluK2
receptor activity. The influx of Ca2? ions through open
kainate receptor ion channels led to oxidation of coelen-
terazine, the cofactor of aequorin, which eventually resul-
ted in the emission of photons. After incubation of the cells
with coelenterazine, the culture medium was replaced with
an assay buffer (Ringer buffer ? 100 mM CaCl2). In a
luminometer (LumiStar, BMG, Germany), 275 lM of
glutamate was applied to the cells and the luminescence
signals were recorded before, during, and after glutamate
application.
Molecular modeling
The homology model of the GluK2 receptor was con-
structed as described previously (Kaczor et al., 2014). The
crystal structure of the AMPA GluA2 receptor (PDB ID:
3KG2) (Sobolevsky et al., 2009) was selected as the main
template. Additional templates were used for the N-termi-
nal domain (crystal structure of the GluK2/GluK5 NTD
tetramer assembly, PDB ID: 3QLV) (Kumar et al., 2011)
and the ligand-binding domain (crystal structure of GluK1
ligand-binding domain (S1S2) in complex with an antag-
onist, PDB ID: 4DLD) (Venskutonyt _e et al., 2012).
Homology modeling was carried out with Modeler v. 9.11
(Eswar et al., 2006). Input conformations of the com-
pounds being investigated were prepared using the LigPrep
protocol from the Schro¨dinger Suite. To sample different
protonation states of the ligands in physiological pH, the
Epik module was used. The structural and electronic
parameters of the ligands were calculated with VegaZZ
v.2.4.0.25 (Pedretti et al., 2004), Gausian09 (Frisch et al.,
2009), and Discovery Studio 3.1. Molecular docking was
performed with Glide from the Schro¨dinger Suite. Molec-
ular dynamics of ligand-receptor complexes were per-
formed as described previously (Kaczor et al., 2014).
Ligand-receptor complexes were inserted into a POPC
lipid bilayer and water with a suitable module of Schro¨-
dinger suite of programs, and sodium and potassium ions
were added to balance the protein charges and then up to a
concentration of 0.15 M. The stability of the ligand-
receptor complexes was assessed by molecular dynamics
simulations with Desmond v. 3.0.3.1 (Bowers et al., 2006)
The ligand-receptor complexes in lipid bilayer were min-
imized and subjected to MD first in the NVT ensemble for
1 ns and then in the NPT ensemble for 20 ns. The fol-
lowing software was also used to visualize the results:
Chimera v.1.5.3 (Pettersen et al., 2004), VegaZZ
v.2.4.0.25, Yasara Structure v.11.9.18 (Krieger and Vriend,
2002), and PyMol v.0.99 (The PyMOL Molecular Graphics
System, Version 0.99, Schro¨dinger, LLC).
Results and discussion
Chemistry
The synthesis of compounds 2–7 is presented in Fig. 2.
Compound 2 was obtained by Fischer indolization reaction.
Alkylation of 2 with dimethyl sulfate resulted in compound
3. The lead compound 1 and derivative 2 were previously
characterized as anti-estrogens (Masatoshi et al., 1993; von
Angerer et al., 1984, 1987, 1990). Compound 3 is a new
compound. Compound 4 was obtained in Friedel–Crafts
acylation of indole as previously described (Guchhait et al.,
2011). Derivative 5 is a new compound and was obtained
in alkylation of 4 with 4-chlorobenzyl chloride. Compound
6 was obtained by cyclization of monophenylhydrazone of
1,3-cyclohexadione (obtained from phenylhydrazine and
1,3-cyclohexadione) in PPA and was characterized previ-
ously (Rodriguez et al., 1989). Compound 7 is a new
compound and was obtained by alkylation of 6 with
4-chlorobenzyl chloride.
Pharmacology
Compounds 3 and 5–7 were tested for their affinity to
GluK2 receptors as described previously (Kaczor et al.,
2012; 2014). The IC50 values for the compounds being
investigated are listed in Table 1. The investigations with
the 3H-kainate binding assay showed no inhibition, which
makes it possible to conclude that the antagonism for
compounds 3 and 5 is of the non-competitive type.
Structural and electronic parameters of novel ligands
In order to address the structure–activity relationship
observed, structural and electronic parameters were cal-
culated for compounds 1, 3, 5, 6, and 7. The data are
Med Chem Res (2015) 24:810–817 813
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Fig. 2 Scheme of reactions
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presented in Tables 2 and 3. The data shown in Table 2
show that the lack of activity of compound 6 may be
explained by the fact that the molecular volume is too low
and the dipole moment too high. The significant difference
between the HOMO and LUMO values (Table 3) indicates
that the compounds are nucleophilic and may participate as
acceptors (through oxygen atoms) in hydrogen bonds with
the binding pocket residues; this is in agreement with our
earlier studies (Kaczor et al., 2012). Moreover, the novel
ligands have more favorable lipophilicity values in com-
parison to the previous series, with the exception of com-
pound 5 (Kaczor et al., 2012).
Ligand-receptor interactions
The binding site for non-competitive GluK2 receptor
antagonists was identified in the receptor transduction
domain, i.e., in the domain which connects the ligand-
binding domain and the transmembrane domain (Fig. 3).
This assumption was made on the basis of studies by
(Balannik et al., 2005) for AMPA receptors as well as on
our earlier molecular modeling studies (Kaczor et al., 2009,
2014). The exact binding site was found on the basis of
sequence differences between the GluK1 and GluK2
receptors in the transduction domain as reported in our
previous studies (Kaczor et al., 2009, 2014). There are no
differences in the S1-M1 linker and in the S2-M4 linker.
Asp823 and Asn824 in GluK1 correspond to Glu808 and
Ser809 in GluK2. The interactions of compounds 3 and 5
with the GluK2 receptor are presented in Fig. 4a, b, c, d,
respectively. There are the following residues in the
binding pocket: Lys544, Pro545, Asn546, Gly547, Pro667,
Asp669, Glu807, Glu808, Lys810, Glu811, and Ala812
which interact with both ligands. Furthermore, in the case
of ligand 5, the pocket is extended with the following
additional residues: Thr753, Gln754, Ile755, and Gly756.
The carbonyl group of ligand 5 forms a hydrogen bond
with the side chain of Lys810. The binding pocket is sit-
uated within one receptor subunit which is in accordance
with our recent studies (Kaczor et al., 2014).
Conclusions
In this paper, we have reported the second series of GluK2
receptor non-competitive antagonists. We obtained two
indole derivatives with activity in the low micromolar
Fig. 3 Model of the GluK2 receptor (Kaczor et al., 2014)
Table 1 Pharmacological activity of novel ligands





7 22 % at 100 lm
Table 2 Structural parameters of novel ligands
Compound Surface, A˚2 Ovality Volume, A˚3 Dipole moment, D
1 557.80 1.6637 324.86 3.97
3 485.2 1.5612 232.00 3.12
5 642.50 1.7163 335.30 3.89
6 379.00 1.4094 171.10 4.92
7 528.50 1.6128 274.00 3.95
Table 3 Electronic and physicochemical parameters of novel ligands
Compound EHOMO, eV ELUMO, eV Lipophilicity
1 -8.03 0.04 4.94
3 -8.10 -0.33 4.65
5 -8.66 -0.52 6.44
6 -8.59 -0.14 2.51
7 -8.57 -0.39 4.96
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range. Furthermore, we found that the designed carbazole
derivatives were not active. The novel non-competitive
antagonists interact with the transduction domain of the
GluK2 receptor, in the same way as the previously reported
series. The binding site is located within one receptor
subunit.
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